KEGG   DRUG: Vantictumab
Entry
D10410                      Drug                                   
Name
Vantictumab (USAN/INN)
Formula
C6322H9722N1674O1988S46
Exact mass
142371.8264
Mol weight
142459.93
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS HYTLSWVRQA PGKGLEWVSV ISGDGSYTYY
ADSVKGRFTI SSDNSKNTLY LQMNSLRAED TAVYYCARNF IKYVFANWGQ GTLVTVSSAS
TKGPSVFPLA PCSRSTSEST AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSNFGTQTYT CNVDHKPSNT KVDKTVERKC CVECPPCPAP PVAGPSVFLF
PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTFRVV
SVLTVVHQDW LNGKEYKCKV SNKGLPAPIE KTISKTKGQP REPQVYTLPP SREEMTKNQV
SLTCLVKGFY PSDIAVEWES NGQPENNYKT TPPMLDSDGS FFLYSKLTVD KSRWQQGNVF
SCSVMHEALH NHYTQKSLSL SPG
(Light chain)
DIELTQPPSV SVAPGQTARI SCSGDNIGSF YVHWYQQKPG QAPVLVIYDK SNRPSGIPER
FSGSNSGNTA TLTISGTQAE DEADYYCQSY ANTLSLVFGG GTKLTVLGQP KAAPSVTLFP
PSSEELQANK ATLVCLISDF YPGAVTVAWK ADSSPVKAGV ETTTPSKQSN NKYAASSYLS
LTPEQWKSHR SYSCQVTHEG STVEKTVAPT ECS
(Disulfide bridge: H22-H96, L22-L87, H'22-H'96, L'22-L'87, H132-L212, H'132-L'212, L135-L194, L'135-L'194, H145-H201, H'145-H'201, H220-H'220, H221-H'221, H224-H'224, H227-H'227, H258-H318, H'258-H'318, H364-H422, H'364-H'422; Glycosylation site: Asn-H294, Asn-H'294)
  Type
Peptide
Efficacy
Antineoplastic, Anti-Frizzled family receptor 7 antibody
  Type
Monoclonal antibody
Target
FZD7 [HSA:8324] [KO:K02432]
  Pathway
hsa04310  Wnt signaling pathway
hsa05200  Pathways in cancer
Brite
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Frizzled / Smoothened family
   Frizzled
    FZD7
     D10410  Vantictumab (USAN/INN)
Other DBs
CAS: 1345009-45-1
PubChem: 172232503
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system